Giuliano Tocci

List of Publications by Year
in descending order

249 papers	5,060 citations	109321 35 h-index	128289 60 g-index
258 all docs	258 docs citations	258 times ranked	7146 citing authors

#	Article	IF	Citations
1	Age and Multimorbidity Predict Death Among COVID-19 Patients. Hypertension, 2020, 76, 366-372.	2.7	330
2	Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2016, 15, 11-34.	2.4	235
3	Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. Journal of Human Hypertension, 2014, 28, 74-79.	2.2	192
4	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. Hypertension, 2020, 75, 302-308.	2.7	177
5	Antihypertensive Treatment and Development of Heart Failure in Hypertension. Archives of Internal Medicine, 2011, 171, 384-94.	3.8	134
6	Role of the reninâ€“angiotensinâ€“aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clinical Science, 2009, 116, 467-477.	4.3	122
7	Blood pressure control in Italy: results of recent surveys on hypertension. Journal of Hypertension, 2007, 25, 1491-1498.	0.5	117
8	Development of heart failure in recent hypertension trials. Journal of Hypertension, 2008, 26, 1477-1486.	0.5	105
9	Tumor necrosis factor-Î± as trigger of platelet activation in patients with heart failure. Blood, 2005, 106, 1992-1994.	1.4	94
10	Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. Critical Reviews in Food Science and Nutrition, 2019, 59, 1605-1618.	10.3	94
11	Markers of Inflammation and Fibrosis Are Related to Cardiovascular Damage in Hypertensive Patients with Metabolic Syndrome. American Journal of Hypertension, 2007, 20, 784-791.	2.0	93
12	Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for) Tj ETQq0 0 0 rgBT /Overlock 10	2.2	93
13	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. Journal of Hypertension, 2012, 30, 1056-1064.	0.5	86
14	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials. American Journal of Hypertension, 2011, 24, 582-590.	2.0	78
15	Blood pressure control in Italy. Journal of Hypertension, 2012, 30, 1065-1074.	0.5	78
16	Right Ventricular Dysfunction in Patients with End-Stage Renal Disease. American Journal of Nephrology, 2010, 32, 432-438.	3.1	75
17	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. Journal of Hypertension, 2020, 38, 412-419.	0.5	70
18	Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2016, 15, 35-54.	2.4	62

#	Article	IF	Citations
19	Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. Journal of Human Hypertension, 2017, 31, 258-262.	2.2	62
20	Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 429-444.	2.2	61
21	Enhanced TNFÎ± and oxidative stress in patients with heart failure: effect of TNFÎ± on platelet O2 - production. Thrombosis and Haemostasis, 2003, 90, 317-325.	3.4	58
22	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 45-52.	2.2	57
23	Is early and fast blood pressure control important in hypertension management?. International Journal of Cardiology, 2018, 254, 328-332.	1.7	56
24	Spontaneous remission of hepatocellular carcinoma after massive gastrointestinal haemorrhage.. BMJ: British Medical Journal, 1990, 300, 641-642.	2.3	55
25	Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 9-25.	2.2	50
26	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 62-69.	0.5	49
27	Arterial hypertension in cancer: The elephant in the room. International Journal of Cardiology, 2019, 281, 133-139.	1.7	48
28	Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Medical Principles and Practice, 2021, 30, 122-130.	2.4	48
29	Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000â€“2005 and 2005â€“2011 hypertension surveys. Journal of Human Hypertension, 2015, 29, 696-701.	2.2	47
30	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. Journal of Hypertension, 2021, 39, 333-340.	0.5	46
31	Revisiting the Relationship Between Blood Pressure and Insulin-Like Growth Factor-1. Hypertension, 2014, 63, 1070-1077.	2.7	45
32	Trends in Prevalence, Awareness, Treatment, and Control of Blood Pressure Recorded From 2004 to 2014 During World Hypertension Day in Italy. Journal of Clinical Hypertension, 2016, 18, 551-556.	2.0	45
33	Hypertension in Young People: Epidemiology, Diagnostic Assessment and Therapeutic Approach. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 381-388.	2.2	43
34	Calcium Channel Blockers and Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 121-130.	2.0	40
35	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis, 2019, 285, 40-48.	0.8	39
36	Early cardiac abnormalities and increased C-reactive protein levels in a cohort of children with sleep disordered breathing. Sleep and Breathing, 2012, 16, 101-110.	1.7	36

#	Article	IF	Citations
37	Prevalence and clinical outcomes of whiteâ€coat and masked hypertension: Analysis of a large ambulatory blood pressure database. Journal of Clinical Hypertension, 2018, 20, 297-305.	2.0	36
38	Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System. Journal of the American Society of Nephrology: JASN, 2006, 17, S36-S43.	6.1	35
39	Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. Journal of Hypertension, 2007, 25, 833-839.	0.5	35
40	Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. European Journal of Internal Medicine, 2015, 26, 255-258.	2.2	35
41	Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 197-202.	2.2	35
42	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. Journal of Nephrology, 2022, 35, 211-221.	2.0	34
43	2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. Journal of Hypertension, 2009, 27, S3-S11.	0.5	31
44	Prediction of Longâ€Term Survival in Chronic Heart Failure by Multiple Biomarker Assessment: A 15â€Year Prospective Followâ€Up Study. Clinical Cardiology, 2010, 33, 700-707.	1.8	31
45	Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. Current Hypertension Reports, 2011, 13, 318-324.	3.5	31
46	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clinical Research in Cardiology, 2021, 110, 1073-1082.	3.3	31
47	Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. Journal of Hypertension, 2009, 27, 941-946.	0.5	29
48	Independent association of ECG abnormalities with microalbuminuria and renal damage in hypertensive patients without overt cardiovascular disease: data from Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2009, 27, 410-417.	0.5	28
49	Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertension Research, 2013, 36, 36-42.	2.7	28
50	Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: Data from the Brisighella Heart Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 907-914.	2.6	27
51	Home Blood Pressure and Telemedicine: A Modern Approach for Managing Hypertension During and After COVID-19 Pandemic. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 1-14.	2.2	26
52	Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. Journal of Hypertension, 2010, 28, 251-258.	0.5	25
53	Aortic root dilatation in hypertensive patients: A multicenter survey in echocardiographic practice. Blood Pressure, 2011, 20, 267-273.	1.5	23
54	Blood Pressure Levels at the Time of Percutaneous Coronary Revascularization and Risk of Coronary In-Stent Restenosis. American Journal of Hypertension, 2016, 29, 509-518.	2.0	23

#	Article	IF	Citations
55	Highlights of ESC/ESH 2018 Guidelines on the Management of Hypertension: What Every Doctor Should Know. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 1-8.	2.2	22
56	Evaluation of Systolic Properties in Hypertensive Patients With Different Degrees of Diastolic Dysfunction and Normal Ejection Fraction. American Journal of Hypertension, 2009, 22, 437-443.	2.0	21
57	Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice. Expert Review of Cardiovascular Therapy, 2010, 8, 811-820.	1.5	21
58	Management of hypertension and stroke prevention: results of the Italian cardiologist survey. International Journal of Clinical Practice, 2009, 63, 207-216.	1.7	20
59	Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction. Clinical Research in Cardiology, 2013, 102, 725-733.	3.3	20
60	Relation between right and left ventricular function in patients undergoing chronic dialysis. Journal of Cardiovascular Medicine, 2013, 14, 289-295.	1.5	20
61	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. Expert Opinion on Drug Safety, 2016, 15, 55-61.	2.4	20
62	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. Journal of Human Hypertension, 2022, 36, 976-982.	2.2	20
63	Renal Artery Denervation for Treating Resistant Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 237-244.	2.2	19
64	Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 241-246.	2.2	19
65	Nocturnal blood pressure patterns and cardiovascular outcomes in patients with masked hypertension. Journal of Clinical Hypertension, 2018, 20, 1238-1246.	2.0	19
66	The reduction of NDUFC2 expression is associated with mitochondrial impairment in circulating mononuclear cells of patients with acute coronary syndrome. International Journal of Cardiology, 2019, 286, 127-133.	1.7	19
67	Use of aliskiren in a â€˜real-lifeâ€™ model of hypertension management. Journal of Hypertension, 2012, 30, 194-203.	0.5	19
68	Renin as a biomarker of cardiovascular disease in clinical practice. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 312-317.	2.6	18
69	Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vascular Health and Risk Management, 2012, 8, 371.	2.3	18
70	Abnormal Regulation of Renin Angiotensin Aldosterone System Is Associated With Right Ventricular Dysfunction inÂHypertension. Canadian Journal of Cardiology, 2014, 30, 188-194.	1.7	18
71	Executive Summary of the 2018 Joint Consensus Document onÂCardiovascular Disease Prevention in Italy. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 327-341.	2.2	18
72	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. Frontiers in Cardiovascular Medicine, 2021, 8, 713652.	2.4	18

#	Article	IF	Citations
73	Erythropoietin in cardiac disease. Journal of Cardiovascular Medicine, 2013, 14, 870-878.	1.5	17
74	Prevalence and Control of Hypertension in Different Macro-Areas in Italy: Analysis of a Large Database by the General Practice. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 387-393.	2.2	17
75	Cardiovascular risk and hypertension control in Italy. Data from the 2015 World Hypertension Day. International Journal of Cardiology, 2017, 243, 529-532.	1.7	17
76	Ambulatory blood pressure and arterial stiffness webâ€based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.8	17
77	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opinion on Pharmacotherapy, 2020, 21, 531-539.	1.8	17
78	Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 91-102.	2.2	17
79	The REassessment of Antihypertensive Chronic Therapy (REACT) Study. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 175-185.	2.2	16
80	Prevalence and Correlates of Echocardiographic Left Atrial Enlargement in Hypertensive Outpatients in Clinical Practice. Clinical and Experimental Hypertension, 2011, 33, 328-335.	1.3	16
81	Pâ€Wave Duration in Lead aVR and the Risk of Atrial Fibrillation in Hypertension. Annals of Noninvasive Electrocardiology, 2015, 20, 167-174.	1.1	16
82	Nation-wide hypertension screening in Italy: data from May Measurements Month 2017â€"Europe. European Heart Journal Supplements, 2019, 21, D66-D70.	0.1	16
83	Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. Expert Opinion on Drug Safety, 2016, 15, 3-10.	2.4	15
84	Adding markers of organ damage to risk score models improves cardiovascular risk assessment: Prospective analysis of a large cohort of adult outpatients. International Journal of Cardiology, 2017, 248, 342-348.	1.7	15
85	Blood Pressure Targets Achievement According to 2018 ESC/ESH Guidelines in Three European Excellence Centers for Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 51-59.	2.2	15
86	Blockade of the neurohormonal systems in heart failure with preserved ejection fraction: A contemporary meta-analysis. International Journal of Cardiology, 2020, 316, 172-179.	1.7	15
87	Trehalose, a natural disaccharide, reduces stroke occurrence in the stroke-prone spontaneously hypertensive rat. Pharmacological Research, 2021, 173, 105875.	7.1	15
88	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1245-1252.	2.6	15
89	Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension. Expert Review of Cardiovascular Therapy, 2007, 5, 767-776.	1.5	14
90	Managing hypertension in cardiology practice according to risk profile. International Journal of Clinical Practice, 2008, 62, 1403-1412.	1.7	14

#	Article	IF	Citations
91	Redefining Blood Pressure Targets in High-Risk Patients?: Lessons From Coronary Endpoints in Recent Randomized Clinical Trials. American Journal of Hypertension, 2011, 24, 1060-1068.	2.0	14
92	Non-Invasive Diagnostic Testing for Coronary Artery Disease in the Hypertensive Patient: Potential Advantages of a Risk Estimation-Based Algorithm. American Journal of Hypertension, 2012, 25, 1226-35.	2.0	14
93	Global cardiovascular risk management in different Italian regions: An analysis of the evaluation of final feasible effect of control training and ultra sensitisation (EFFECTUS) educational program. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 635-642.	2.6	14
94	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 463-472.	2.2	14
95	Implications of Guidelines for Hypertension Management in Europe. Circulation Research, 2019, 124, 972-974.	4.5	14
96	Reclassification of Hypertensive Outpatients According to New US Guidelines on High Blood Pressure. American Journal of Hypertension, 2019, 32, 77-87.	2.0	14
97	Recommendations for Cardiovascular Prevention During the Sars-Cov-2 Pandemic: An Executive Document by the Board of the Italian Society of Cardiovascular Prevention. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 373-377.	2.2	14
98	Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum. Frontiers in Physiology, 2021, 12, 652163.	2.8	14
99	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 129-135.	2.2	14
100	Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Review of Cardiovascular Therapy, 2009, 7, 115-123.	1.5	13
101	Global Cardiovascular Risk Assessment in Different Clinical Settings. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 55-63.	2.2	13
102	Echocardiography in clinical practice: the burden of arterial hypertension. A multicenter Italian survey. Journal of Human Hypertension, 2010, 24, 395-402.	2.2	13
103	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 37-47.	2.2	13
104	A Novel Electrocardiographic Tâ€Wave Measurement (Tpâ€Te Interval) as a Predictor of Heart Abnormalities in Hypertension: A New Opportunity for Firstâ€Line Electrocardiographic Evaluation. Journal of Clinical Hypertension, 2015, 17, 441-449.	2.0	13
105	Favourable impact of statin use on diastolic blood pressure levels. Journal of Hypertension, 2017, 35, 2086-2094.	0.5	13
106	New approach to blood pressure control: Triple combination pill. Trends in Cardiovascular Medicine, 2020, 30, 72-77.	4.9	13
107	Clinical Management of Patients with Hypertension and High Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 107-117.	2.2	12
108	Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 850-857.	2.6	12

#	Article	IF	Citations
109	Prevalence of metabolic syndrome in the clinical practice of general medicine in Italy. Cardiovascular Diagnosis and Therapy, 2015, 5, 271-9.	1.7	12
110	Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial. Aging Clinical and Experimental Research, 2005, 17, 46-53.	2.9	12
111	The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. Journal of Hypertension, 2022, 40, 704-711.	0.5	12
112	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. International Journal of Cardiology, 2011, 149, 250-252.	1.7	11
113	Impact of Diabetes Mellitus on the Clinical Management of Global Cardiovascular Risk: Analysis of the Results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) Educational Program. Clinical Cardiology, 2011, 34, 560-566.	1.8	11
114	How to Improve Effectiveness and Adherence to Antihypertensive Drug Therapy: Central Role of Dihydropyridinic Calcium Channel Blockers in Hypertension. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 25-34.	2.2	11
115	Conventional and new electrocardiographic criteria for hypertensionâ€mediated cardiac organ damage: A narrative review. Journal of Clinical Hypertension, 2019, 21, 1863-1871.	2.0	11
116	Understanding and treating hypertension in diabetic populations. Cardiovascular Diagnosis and Therapy, 2015, 5, 353-63.	1.7	11
117	Olmesartan in the Treatment of Hypertension in Elderly Patients: a Review of the Primary Evidence. Drugs and Aging, 2013, 30, 987-998.	2.7	10
118	Hypertension in the elderly: which are the blood pressure threshold values?. European Heart Journal Supplements, 2019, 21, B105-B106.	0.1	10
119	Antihypertensive therapy and cerebrovascular protection. Current Opinion in Nephrology and Hypertension, 2006, 15, 498-504.	2.0	9
120	End-Organ Protection in Patients with Hypertension. Drugs, 2011, 71, 1003-1017.	10.9	9
121	Pathophysiology of biventricular dysfunction during hemodialysis: Emerging concepts. International Journal of Cardiology, 2012, 155, 478-479.	1.7	9
122	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 313-329.	2.2	9
123	Achievement of multiple therapeutic targets for cardiovascular disease prevention: Retrospective analysis of real practice in Italy. Clinical Cardiology, 2018, 41, 788-796.	1.8	9
124	Legacy Effect in the Treatment of Hypertension: Persistent Cardiovascular Protection after Conclusion of Randomized Clinical Trials in Hypertension. Current Hypertension Reports, 2019, 21, 85.	3.5	9
125	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. European Journal of Preventive Cardiology, 2022, 29, 1501-1509.	1.8	9
126	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 353-359.	2.2	9

#	Article	IF	Citations
127	Hypertension and Heart Failure: Role of Neurohormonal Mechanisms. Clinical and Experimental Hypertension, 2004, 26, 603-610.	1.3	8
128	Triple combination therapy to improve blood pressure control: experience with olmesartanâ€“amlodipineâ€“hydrochlorothiazide therapy. Expert Opinion on Pharmacotherapy, 2012, 13, 2687-2697.	1.8	8
129	Hypertension in Premenopausal Women: Is There Any Difference?. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 195-199.	2.2	8
130	Therapeutic Approach to Hypertension Urgencies and Emergencies During Acute Coronary Syndrome. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 253-259.	2.2	8
131	Blood Pressure Target Achievement Under Monotheraphy: A Real-Life Appraisal. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 587-596.	2.2	8
132	Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. Journal of Hypertension, 2020, 38, 1005-1015.	0.5	8
133	Ventriculo-arterial coupling in the intensive cardiac care unit: A non-invasive prognostic parameter. International Journal of Cardiology, 2022, 348, 85-89.	1.7	8
134	Long-Term Tolerability and Efficacy of the Fixed Combination of Manidipine and Delapril in Patients with Essential Hypertension. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 81-86.	2.2	7
135	Angiotensin II-receptor antagonist in the treatment of hypertension. Current Hypertension Reports, 2005, 7, 287-293.	3.5	7
136	An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 19-30.	2.2	7
137	Modern Clinical Management of Arterial Hypertension. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 3-11.	2.2	7
138	The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study. International Journal of Cardiology, 2012, 158, 158-160.	1.7	7
139	Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter?. ISRN Cardiology, 2014, 2014, 1-7.	1.6	7
140	National Survey on Excellence Centers and Reference Centers for Hypertension Diagnosis and Treatment: Geographical Distribution, Medical Facilities and Diagnostic Opportunities. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 29-36.	2.2	7
141	Impact of Hypertension on Global Cardiovascular Risk Stratification: Analysis of a Large Cohort of Outpatient Population in Italy. Clinical Cardiology, 2015, 38, 39-47.	1.8	7
142	Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. Internal and Emergency Medicine, 2015, 10, 943-954.	2.0	7
143	Hypertensive crisis management in the emergency room. Journal of Hypertension, 2020, 38, 33-34.	0.5	7
144	Cardiovascular Risk Profile in 14???513 Patients with Essential Hypertension Followed by Italian Specialist Physicians. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 165-173.	2.2	6

#	Article	IF	Citations
145	Rethinking targets of blood pressure and guidelines for hypertension clinical management. Nephrology Dialysis Transplantation, 2010, 25, 3465-3471.	0.7	6
146	An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 73-83.	2.2	6
147	Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: results of the Italian Hypertension and Heart Survey. Journal of Human Hypertension, 2015, 29, 409-416.	2.2	6
148	Hypertension Across the Atlantic: A Sprint or a Marathon?. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 99-102.	2.2	6
149	Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24â€hour ambulatory blood pressure database. Journal of Clinical Hypertension, 2018, 20, 967-975.	2.0	6
150	24-Hour ambulatory blood pressure levels and control in a large cohort of adult outpatients with different classes of obesity. Journal of Human Hypertension, 2019, 33, 298-307.	2.2	6
151	Preclinical effects of healthy obesity on inappropriate left ventricular mass and systolic function. International Journal of Cardiology, 2013, 167, 3047-3049.	1.7	5
152	Synergic effects of renin and aldosterone on right ventricular function in hypertension. Journal of Cardiovascular Medicine, 2015, 16, 831-838.	1.5	5
153	New Opportunities for Monitoring Blood Pressure Control and Awareness in the Population: Insights from 12-Year Editions of the World Hypertension Day. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 333-335.	2.2	5
154	Hypertension in Patients with Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2016, 18, 127.	2.9	5
155	Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 243-253.	2.2	5
156	Increased arterial stiffness and haemorrhagic transformation in ischaemic stroke after thrombolysis: A new marker of risk for cerebrovascular events and complications. International Journal of Cardiology, 2017, 243, 471-472.	1.7	5
157	Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: results of the Italian hypertension and brain survey. Clinical Hypertension, 2017, 23, 10.	2.0	5
158	Antihypertensive drugs and the risks of cancer: More fakes than facts. European Journal of Preventive Cardiology, 2021, 28, 1323-1326.	1.8	5
159	Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies. Angiology, 2020, 71, 217-225.	1.8	5
160	An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 73-83.	2.2	5
161	PLASMAPHERESIS FOR LATE-STAGE TRYPANOSOMIASIS. Lancet, The, 1989, 333, 1200.	13.7	4
162	Angiotensin II receptor blockers and coronary artery disease: 'presumed innocents'. European Heart Journal, 2005, 27, 1506-1507.	2.2	4

#	Article	IF	Citations
163	Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy. Expert Review of Cardiovascular Therapy, 2011, 9, 829-840.	1.5	4
164	Synergic effect of high renin and aldosterone levels on inappropriate left ventricular mass and systolic function: A tissue Doppler study. International Journal of Cardiology, 2013, 168, 4934-4936.	1.7	4
165	Clinical management of patients with hypertension and high cardiovascular risk in specialised centers and in general practice. Analysis from an Italian Survey Questionnaire. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 866-874.	2.6	4
166	Multivariate risk assessment and risk score cards in hypertension. Vascular Health and Risk Management, 2007, 3, 313-20.	2.3	4
167	Current applications and limitations of European guidelines on blood pressure measurement: implications for clinical practice. Internal and Emergency Medicine, 2022, 17, 645-654.	2.0	4
168	Socioeconomic status as determinant of individual cardiovascular risk. Atherosclerosis, 2022, 346, 82-83.	0.8	4
169	Protocol for an Observational Blood Pressure Study. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 11-14.	2.2	3
170	Prevalence of â€˜Borderlineâ€™ Values of Cardiovascular Risk Factors in the Clinical Practice of General Medicine in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 43-51.	2.2	3
171	Olmesartan medoxomil for the treatment of hypertension in children and adolescents. Vascular Health and Risk Management, 2011, 7, 177.	2.3	3
172	New Oral Anticoagulants in Non-Valvular Atrial Fibrillation. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 53-60.	2.2	3
173	Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 255-263.	2.2	3
174	Novel blood pressure targets in patients with high-normal levels and grade 1 hypertension: Room for monotherapy?. International Journal of Cardiology, 2019, 291, 105-111.	1.7	3
175	Immigration Emergency in Italy: The Impact of Socioeconomic Status on Blood Pressure Levels and Control. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 467-473.	2.2	3
176	Effects of dual inhibition of reninâ€“angiotensinâ€“aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits. Internal and Emergency Medicine, 2020, 15, 373-379.	2.0	3
177	Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion. European Journal of Integrative Medicine, 2020, 37, 101164.	1.7	3
178	Prevalence and clinical characteristics of isolated systolic hypertension in young: analysis of 24â€‰h ambulatory blood pressure monitoring database. Journal of Human Hypertension, 2022, 36, 40-50.	2.2	3
179	Global Cardiovascular Risk Management in Primary Prevention. Current Vascular Pharmacology, 2012, 10, 709-711.	1.7	3
180	Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2022, 29, 105-113.	2.2	3

#	Article	IF	Citations
181	Therapeutic implications of recent megatrials in hypertension: in favor of new drugs. Journal of Nephrology, 2007, 20 Suppl 12, S12-8.	2.0	3
182	How to Manage Metabolic Syndrome. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 231-238.	2.2	2
183	Use of predictive markers to improve cardiovascular protection. Future Cardiology, 2007, 3, 447-456.	1.2	2
184	High Blood Pressure, Ventricular Tachycardia and Transient Left Ventricular Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 57-59.	2.2	2
185	Impact of physiciansâ€™ age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme. International Journal of Clinical Practice, 2011, 65, 649-657.	1.7	2
186	Tpâ€“Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. International Journal of Cardiology, 2016, 221, 881-885.	1.7	2
187	EFFECT OF RESVERATROL ON BLOOD PRESSURE. Journal of Hypertension, 2018, 36, e123.	0.5	2
188	Epidemiological Impact and Clinical Consequences of Masked Hypertension: A Narrative Review. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 195-201.	2.2	2
189	Hypertension Management and Control in Italy: A Real-World Survey in Elderly Patients. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 425-426.	2.2	2
190	Adverse Effects of Statins. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 141???148.	2.2	1
191	Upcoming Challenges for Training in Cardiology. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 201-206.	2.2	1
192	Central Adiposity, Blood Pressure Variability and Endothelial Activation in Light-to-Moderate Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	2.2	1
193	Shooting beyond score. Journal of Hypertension, 2012, 30, 1909-1910.	0.5	1
194	Strategies to improve control of blood pressure in hypertension: moving towards a 70% objective. Expert Review of Cardiovascular Therapy, 2013, 11, 653-656.	1.5	1
195	An atypical clinical presentation of renovascular hypertension. International Journal of Cardiology, 2014, 177, e107-e110.	1.7	1
196	Time Trend Analysis of Hypertension Prevalence, Awareness, Treatment and Control in Italy: Novel Insights from Recent National Surveys in the General Population. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 103-105.	2.2	1
197	[BP.03.03] CARDIOVASCULAR RISK AND HYPERTENSION CONTROL IN ITALY. DATA FROM THE 2015 WORLD HYPERTENSION DAY. Journal of Hypertension, 2017, 35, e176-e177.	0.5	1
198	Measuring Central or Peripheral Blood Pressure Levels? That is the Question in the Modern Clinical Practice of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 415-416.	2.2	1

#	Article	IF	Citations
199	Search of multiple markers of organ damage for better cardiovascular risk stratification in hypertension: Role of â€œSHATSâ€•syndrome in the clinical practice. International Journal of Cardiology, 2018, 263, 154-155.	1.7	1
200	Predictive Role of High Blood Pressure for the Incidence of Metabolic Syndrome. Cardiology, 2019, 142, 232-234.	1.4	1
201	Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?. Internal and Emergency Medicine, 2019, 14, 903-905.	2.0	1
202	SERUM URIC ACID, INDEPENDENTLY OF ARTERIAL HYPERTENSION, PREDICTS NON-FATAL INCIDENT CEREBROVASCULAR EVENTS IN AN ITALIAN LARGE COHORT OF MEN AND WOMEN. SEARCH FOR A CUT-OFF VALUE. Journal of Hypertension, 2019, 37, e221-e222.	0.5	1
203	Excess of dyslipidemia in low income countries: The case of Colombia in the PURE study. International Journal of Cardiology, 2019, 290, 152-153.	1.7	1
204	Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension. Cardiology, 2020, 145, 599-600.	1.4	1
205	Real-life appraisal on blood pressure targets achievement in adult outpatients at high cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 472-480.	2.6	1
206	ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 255-262.	2.2	1
207	A Review of Angiotensin Receptor Blocker-based Therapies at all Levels of Cardiovascular Risk. European Cardiology Review, 2011, 7, 254.	2.2	1
208	Follow-up, study design and outcome parameters. EuroIntervention, 2013, 9, R96-R100.	3.2	1
209	Imipenem-cilastatin for the treatment of bacterial complications in the immunocompromised host. Current Therapeutic Research, 1992, 52, 753-756.	1.2	0
210	Biological relevance of a proANP molecular variant in human endothelial cells. American Journal of Hypertension, 2003, 16, A67.	2.0	0
211	Oxidative Stress and Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2003, 10, 27-33.	2.2	0
212	410 Altered TCR-mediated signalling in T cells from HCV-chronically infected patients. Journal of Hepatology, 2004, 40, 122.	3.7	0
213	Treatment of High-Risk Hypertensive Patients. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 13-19.	2.2	0
214	Evaluation of Intermediate Endpoints: Clinical Implications in the Management of Arterial Hypertension. Current Hypertension Reviews, 2007, 3, 196-202.	0.9	0
215	JustificaciÃ³n de la terapia combinada con IECA y bloqueadores de los canales de calcio en la hipertensiÃ³n. Hipertension, 2007, 24, 256-260.	0.0	0
216	Angiotensin II Receptor Antagonists. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 39-47.	2.2	0

#	Article	IF	Citations
217	Chronic AC-SDKP Administration Reduces Cardiac and Renal Perivascular Fibrosis in Diabetic Rats. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	2.2	0
218	Conventional and Tissue Doppler Evaluation of Systolic and Diastolic Function in a Cohort of Paediatric Obese Subjects. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	2.2	0
219	Impact of Diabetes and Impaired Glucose Tolerance (IGT) on Complications and Hospitalisation in Patients with Acute Coronary Syndrome. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	2.2	0
220	1.10 Superiority of Apolipoproteins Compared to Non-HDL Cholesterol in Predicting the Presence of Coronary Disease in Hypertensive Patients with Ischemic Heart Disease. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 180-180.	2.2	0
221	1.11 Prevalence of Metabolic Alterations In Hypertensive Patients with Stable vs Unstable Angina. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 181-181.	2.2	0
222	Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines. Current Hypertension Reviews, 2008, 4, 234-240.	0.9	0
223	Fixed combination therapies based on direct renin inhibition: a commentary to the ACCELERATE trial. Clinical Investigation, 2011, 1, 605-610.	0.0	0
224	Network Meta-analysis of Heart Failure Prevention by Antihypertensive Drugsâ€"Reply. Archives of Internal Medicine, 2011, 171, 472.	3.8	0
225	A Survey on Blood Pressure Levels and Hypertension Control in a Sample of the Italian General Population. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 129-135.	2.2	0
226	Renin-angiotensin system blockers increase risk of angio-oedema. Evidence-Based Medicine, 2013, 18, e52-e52.	0.6	0
227	Reducing therapeutic inertia to improve blood pressure control. Journal of Hypertension, 2014, 32, 988-989.	0.5	0
228	Combination Therapy for the Clinical Management of Hypertension. , 2015, , 887-902.		0
229	Use of Fixed Combination Therapies to Improve Blood Pressure Control in the Clinical Management of Hypertension: A Key Opportunity. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 427-428.	2.2	0
230	Managing hypertension after acute coronary syndrome. Journal of Hypertension, 2015, 33, 700-701.	0.5	0
231	Metabolic approaches to antihypertensive treatment in diabetic patients. Hypertension Research, 2015, 38, 802-803.	2.7	0
232	Exploring New Options for Cardiovascular Disease Prevention May Improve Patientsâ€™ Quality of Life and Outcomes. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 259-260.	2.2	0
233	Patient with Essential Hypertension and Diastolic Dysfunction. Practical Case Studies in Hypertension Management, 2016, , 23-41.	0.0	0
234	Educational Interventions May Promote Better Blood Pressure Control in Russia. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 351-352.	2.2	0

#	Article	IF	Citations
235	[OP.3C.01] COMPARISON BETWEEN EUROPEAN SYSTEMATIC CORONARY RISK EVALUATION AND ITALIAN CUORE ALGORITHMS IN ADULT OUTPATIENTS FOLLOWED BY GENERAL PRACTITIONERS AND SPECIALISED CENTRES. Journal of Hypertension, 2017, 35, e30.	0.5	0
236	[OP.6A.06] PREVALENCE AND CLINICAL CHARACTERISTICS OF TRUE MASKED HYPERTENSION COMPARED TO REVERSE AND ISOLATED NOCTURNAL MASKED HYPERTENSION. Journal of Hypertension, 2017, 35, e56.	0.5	0
237	[PP.01.17] ADDING HYPERTENSION-RELATED MARKERS OF ORGAN DAMAGE TO RISK SCORE MODELS IMPROVES CARDIOVASCULAR RISK ASSESSMENT. Journal of Hypertension, 2017, 35, e97.	0.5	0
238	[PP.04.18] COMPARISON AMONG DIFFERENT ELECTROCARDIOGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY. Journal of Hypertension, 2017, 35, e116.	0.5	0
239	Hypertension and social determinants in a cohort of migrants acceding an outpatient clinic in Rome. European Journal of Public Health, 2017, 27, .	0.3	0
240	Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 5-7.	2.2	0
241	Use of Fixed-Dose Combinations in Hypertension and Cardiovascular Disease Prevention. Updates in Hypertension and Cardiovascular Protection, 2018, , 225-235.	0.1	0
242	AWARENESS OF MAJOR CARDIOVASCULAR RISK FACTORS AND ITS RELATIONSHIP WITH MARKERS OF VASCULAR AGING. Journal of Hypertension, 2019, 37, e97.	0.5	0
243	How to Improve Patientsâ€™ Adherence to Antihypertensive Therapy: A Simple Solution for a Big Trouble. American Journal of Hypertension, 2019, 32, 141-142.	2.0	0
244	Are we really sure about the pycnogenol antihypertensive effect?. Pharmacological Research, 2020, 151, 104543.	7.1	0
245	White-coat and masked hypertension and coronary artery disease: are they related or not?. Hypertension Research, 2020, 43, 151-152.	2.7	0
246	High Resolution Signal Averaged Electrocardiography May Improve Diagnosis of Atrial Fibrillation and Reduce Stroke. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 265-266.	2.2	0
247	A Plea for Smoking-Free Policies in COVID-19 Times: Cardiovascular Prevention as an Ally in Coronavirus Containment. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 325-326.	2.2	0
248	Involvement of Health Professionals: From the General Practitioner to the Hypertension Specialist and the Hypertension Center. , 2013, , 181-191.		0
249	Diastolic Blood Pressure Levels and Cardiovascular Risk in Elderly Women: The Need for a Personalized Approach. American Journal of Hypertension, 0, , .	2.0	0